VPS26B: A Potential Drug Target and Biomarker (G112936)

Target Name: VPS26B

NCBI ID: G112936

VPS26B

VPS26B: A Potential Drug Target and Biomarker

Vacuolar protein sorting-associated protein 26B (VPS26B) is a protein that plays a crucial role in the transport of different proteins across the membrane of the endoplasmic reticulum (ER). It is a member of the VPS family, which is known for their ability to transport a wide variety of proteins across the ER membrane. VPS26B is unique due to its unique localization to the ER-endowsome, a structure that is involved in the delivery of proteins to the ER.

The ER-endowsome is a complex structure that is composed of multiple proteins that help to transport different proteins across the ER membrane. The endowsome is composed of two major components: the transmembrane protein T-tag and the cytoplasmic protein N-terminal translocation domain (NTD). The T-tag is responsible for the protein's access to the ER-endowsome, while the NTD is responsible for the protein's cytoplasmic localization.

VPS26B is a key protein that is involved in the transport of different proteins across the ER-endowsome. It is able to interact with the NTD of other proteins and help to transport them across the ER membrane. This interaction between VPS26B and other proteins is important for the proper functioning of the ER-endowsome.

In addition to its role in the ER-endowsome, VPS26B is also involved in the regulation of protein function. It has been shown to play a role in the degradation of certain proteins, as well as in the regulation of protein stability.

Given its unique localization to the ER-endowsome and its involvement in the regulation of protein function, VPS26B is a potential drug target. Drugs that target VPS26B have the potential to interfere with its ability to transport proteins across the ER-endowsome, leading to changes in the expression and stability of certain proteins. This could have therapeutic implications for a wide range of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease.

In addition to its potential as a drug target, VPS26B is also a potential biomarker. Its unique localization to the ER-endowsome makes it a potential target for imaging technologies, such as affinity purification mass spectrometry (AP-MS) and immunofluorescence. These technologies can be used to study the localization and function of VPS26B in live cells, providing valuable information about its behavior in the ER.

Overall, VPS26B is a unique and highly relevant protein that has the potential to be a drug target and biomarker. Further research is needed to fully understand its role in the ER-endowsome and its potential as a therapeutic intervention.

Protein Name: VPS26 Retromer Complex Component B

Functions: Acts as component of the retromer cargo-selective complex (CSC). The CSC is believed to be the core functional component of retromer or respective retromer complex variants acting to prevent missorting of selected transmembrane cargo proteins into the lysosomal degradation pathway. The recruitment of the CSC to the endosomal membrane involves RAB7A and SNX3. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX3-retromer mediates the retrograde transport of WLS distinct from the SNX-BAR retromer pathway. The SNX27-retromer is believed to be involved in endosome-to-plasma membrane trafficking and recycling of a broad spectrum of cargo proteins. The CSC seems to act as recruitment hub for other proteins, such as the WASH complex and TBC1D5. May be involved in retrograde transport of SORT1 but not of IGF2R. Acts redundantly with VSP26A in SNX-27 mediated endocytic recycling of SLC2A1/GLUT1 (By similarity)

The "VPS26B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS26B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets